These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 16497294)

  • 21. Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells.
    Newman-Tancredi A; Heusler P; Martel JC; Ormière AM; Leduc N; Cussac D
    Int J Neuropsychopharmacol; 2008 May; 11(3):293-307. PubMed ID: 17897483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
    Oz M; Zhang L; Rotondo A; Sun H; Morales M
    Synapse; 2003 Dec; 50(4):303-13. PubMed ID: 14556235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
    Heusler P; Newman-Tancredi A; Castro-Fernandez A; Cussac D
    Neuropharmacology; 2007 Mar; 52(4):1106-13. PubMed ID: 17239906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
    Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
    Kleven MS; Barret-Grévoz C; Bruins Slot L; Newman-Tancredi A
    Neuropharmacology; 2005 Aug; 49(2):135-43. PubMed ID: 15996562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
    Depoortère R; Barret-Grévoz C; Bardin L; Newman-Tancredi A
    Eur J Pharmacol; 2008 Nov; 597(1-3):34-8. PubMed ID: 18773888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
    Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A
    Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats.
    Auclair AL; Galinier A; Besnard J; Newman-Tancredi A; Depoortère R
    Psychopharmacology (Berl); 2007 Jul; 193(1):45-54. PubMed ID: 17393144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
    Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
    J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
    Novi F; Millan MJ; Corsini GU; Maggio R
    J Neurochem; 2007 Aug; 102(4):1410-24. PubMed ID: 17532788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
    Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B
    Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
    Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
    Cussac D; Duqueyroix D; Newman-Tancredi A; Millan MJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):168-77. PubMed ID: 12110994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
    Tadori Y; Miwa T; Tottori K; Burris KD; Stark A; Mori T; Kikuchi T
    Eur J Pharmacol; 2005 May; 515(1-3):10-9. PubMed ID: 15894311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
    Gogos A; Bogeski M; van den Buuse M
    Behav Pharmacol; 2008 Sep; 19(5-6):548-61. PubMed ID: 18690109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2011 Oct; 668(3):355-65. PubMed ID: 21816144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.